Table 2 Trial demographics by treatment group

From: The role of recombinant human CC10 in the prevention of chronic pulmonary insufficiency of prematurity

DemographicPlacebo (N = 22)1.5 mg/kg rhCC10 (N = 22)Placebo (N = 21)5 mg/kg rhCC10 (N = 23)
Region—N (%)
  US22 (100)22 (100)10 (48)11 (48)
  PolandN/AN/A11 (52)12 (52)
White—N (%)9 (41)12 (55)15 (71)18 (78)
Hispanic ethnicity—N (%)5 (23)7 (32)5 (24)5 (22)
Female—N (%)12 (55)8 (36)8 (38)12 (52)
Mean gestational age at birth (SD)—weeks26.1 (1.3)26.5 (1.1)27.0 (1.3)26.6 (1.2)
Mean birth weight (SD)—g877.4 (170.9)859.3 (140.9)885.5 (173.9)867.2 (187.2)
Median 5 min APGAR score (IQR)8 (7, 8)7 (6, 8)7 (7, 8)7 (6, 8)
  1. SD standard deviation, IQR interquartile range, rhCC10 recombinant human Club cell 10-kilodalton protein, N/A not applicable